Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

Inclusion Criteria: * 18 years or older * histologically or cytologically confirmed advanced or refractory solid tumour and no longer eligible for approved, available standard therapies. Tumour types must have: 1. proven MET activating mutations, determined by previous next generation sequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, or 2. proven amplification (≥ 10 copies) on archived tumour tissue. or 3. Hereditary Renal Papillary Cancer * measurable disease in accordance with RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 * adequate bone marrow function, without the support of cytokines * adequate liver function * adequate renal function * agree to follow the contraception requirements of the trial * signed informed consent, indicating study patients understand the purpose of and procedures required for the study and are willing to participate in the study. Exclusion Criteria: * major surgery within 3 weeks before enrollment * chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy, or any other study drug within 3 weeks before study drug administration * antibody based cancer therapy within 4 weeks before administration of the first dose of DO-2 * patients who became progressive on previous treatment with a MET-kinase inhibitor * patients with brain metastases are excluded unless all of the following criteria are met: 1. CNS lesions are asymptomatic and previously treated 2. No ongoing requirement for corticosteroids as therapy for CNS metastases 3. Imaging demonstrates stability of disease \> 28 days from last treatment for CNS metastases * leptomeningeal involvement (leptomeningeal carcinomatosis) * history of uncontrolled heart disease including unstable angina, congestive heart failure, myocardial infarction within preceding 12 months, clinically significant rhythm or conduction abnormality, congenital long QT syndrome, obligate use of a cardiac pacemaker, QTc at screening greater than 450 milliseconds in males and greater than 470 milliseconds in females * uncontrolled arterial hypertension despite appropriate therapy * positive pregnancy test (urinary beta-hCG) at screening (applicable to women of child-bearing potential who are sexually active) * mental status alteration or history of major psychiatric illness, which may potentially impair patient's compliance with study procedures * signs and symptoms of active infection requiring systemic therapy * other medical condition (e.g. pre-existing kidney dysfunction) that in the opinion of the investigator makes it undesirable for a patient to participate